Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Kelleher Financial Advisors

Kelleher Financial Advisors increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 1.8% during the fourth quarter, HoldingsChannel reports. The fund owned 2,472 shares of the medical research company’s stock after buying an additional 43 shares during the period. Kelleher Financial Advisors’ holdings in Amgen were worth $644,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Capital Performance Advisors LLP purchased a new stake in shares of Amgen in the third quarter valued at $25,000. Legacy Investment Solutions LLC purchased a new position in shares of Amgen in the 3rd quarter worth about $29,000. Hershey Financial Advisers LLC purchased a new position in shares of Amgen in the 2nd quarter worth about $30,000. Matrix Trust Co acquired a new stake in shares of Amgen in the third quarter valued at about $36,000. Finally, Livelsberger Financial Advisory acquired a new stake in Amgen during the 3rd quarter valued at approximately $56,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

AMGN stock opened at $273.44 on Thursday. The stock has a 50-day moving average price of $272.47 and a two-hundred day moving average price of $306.67. The stock has a market cap of $146.98 billion, a PE ratio of 35.01, a price-to-earnings-growth ratio of 2.78 and a beta of 0.56. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating the consensus estimate of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. During the same quarter last year, the company earned $4.96 EPS. Amgen’s revenue for the quarter was up 23.2% compared to the same quarter last year. Equities analysts forecast that Amgen Inc. will post 19.57 EPS for the current fiscal year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be paid a $2.38 dividend. This is an increase from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.48%. The ex-dividend date is Friday, February 14th. Amgen’s dividend payout ratio (DPR) is 115.24%.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on AMGN. Robert W. Baird reiterated an “underperform” rating and issued a $215.00 target price on shares of Amgen in a research report on Wednesday, September 25th. StockNews.com cut Amgen from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Barclays lifted their price target on Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a research report on Monday, October 7th. Bank of America restated an “underperform” rating and issued a $256.00 target price on shares of Amgen in a report on Tuesday, December 10th. Finally, Redburn Partners decreased their target price on Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $314.91.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.